Fatemeh Rahbar¹, Avid Farhang Fagheh², Ayda Khosravi², Siavash Shariatzadeh^2,3,*, Reza Akhavan-Sigari⁴

Molecular & Cellular Biomechanics, Vol.18, No.4, pp. 187-199, 2021, DOI:10.32604/mcb.2021.017750 - 27 October 2021

Abstract The protein ERp57 is a stress-responsive protein, mainly exists in the endoplasmic reticulum (ER), and a small amount in the cell membrane, cytoplasm, nucleus and mitochondria, which is involved in the signal transduction from the cell surface, the regulation process that occurs in the nucleus, and the formation of polymer protein complexes involved in DNA repair. Various degrees of ERp57 dysregulation has been observed in many types of non-communicable diseases especially in cancers. Previous studies showed that the expression of ERp57 could play a key role in occurrence and development of cancers such as breast… More >

Elda A. Flores-Contreras¹, Everardo González-González^2,3, Ana I. Zarazúa-Niño¹, Elsa N. Garza-Treviño¹, Natalia Martínez-Acuña¹, Viviana C. Zomosa-Signoret⁴, Román Vidaltamayo⁴, Gerardo E. Muñoz-Maldonado⁵, Raquel Garza-Guajardo⁶, Manuel de J. García-Solís⁷, Alejandro Abarca-Blanco³, Ana M. G. Rivas-Estilla¹, Carlos Córdova-Fletes^1,*

Oncologie, Vol.23, No.3, pp. 373-392, 2021, DOI:10.32604/oncologie.2021.017786 - 26 September 2021

Abstract Breast cancer (BC) is one of the leading causes of death in women worldwide. A major challenge in BC is chemoresistance, which is often modulated by epigenetic regulators such as long non-coding RNAs (lncRNAs). Because these regulator lncRNAs may play diverse roles, determining their specific pathways and/or functions is crucial to identify possible biomarkers and/or therapeutic targets for BC. In this study, we used gene expression microarrays in order to identify lncRNAs related to the BC biology. We found, among six differentially expressed (DE) lncRNAs, that the expression of lnc-ERP44-3:6 was consistently down-regulated in all breast… More >

Zheng Wang¹, Yongxia He¹, Yuwei Song¹, Yue Wang², Feng Chen^3,*

Oncologie, Vol.23, No.2, pp. 177-184, 2021, DOI:10.32604/Oncologie.2021.014773 - 22 June 2021

Abstract Hepatocellular carcinoma (HCC) is a malignant tumor with high morbidity and mortality. At present, diagnostic methods such as imaging observation, serum testing and tissue biopsy, as well as treatment methods such as surgical resection, radiotherapy, and chemotherapy have certain limitations in clinical interventions for HCC due to the complex pathogenesis and drug resistance of liver cancer, which seriously affect the survival and prognosis of patients. As a large-scale cytokine, microRNA (miRNA) plays an important role in regulating various life activities of cells. Extensive evidence proved that certain miRNAs are specifically expressed in the tissues and More >

Ziyi Wang^*, Xinyu Zhang^*, Xuedong Zhang^†, Xuedong Jiang^‡, Wenya Li^*

Oncology Research, Vol.28, No.9, pp. 913-927, 2020, DOI:10.3727/096504021X16310057751016

Abstract Long intergenic nonprotein-coding RNA 1703 (LINC01703) has diagnostic significance in lung adenocarcinoma. However, its specific roles in non-small cell lung cancer (NSCLC) and downstream mechanisms have not been investigated. In the current study, we characterized the role of LINC01703 in NSCLC malignancy and elucidated its detailed mechanism of action. LINC01703 expression was measured by qRT-PCR. The regulatory effects of LINC01703 on the malignancy of NSCLC cells were assessed by multiple functional experiments. The targeted interaction was confirmed by RNA immunoprecipitation and luciferase reporter assays. Herein, overexpression of LINC01703 in NSCLC was indicated in the TCGA… More >

Huan Ma¹, Cong Nie¹, Ying Chen, Jinmiao Li, Yanjie Xie, Zhixin Tang, Yang Gao, Siming Ai, Yuxiang Mao, Qian Sun, Rong Lu

Oncology Research, Vol.28, No.7-8, pp. 745-761, 2020, DOI:10.3727/096504021X16130322409507

Abstract Cell cycle deregulation is involved in the pathogenesis of many cancers and is often associated with protein kinase aberrations, including the polo-like kinase 1 (PLK1). We used retinoblastoma, an intraocular malignancy that lacks targeted therapy, as a disease model and set out to reveal targetability of PLK1 with a small molecular inhibitor ON-01910.Na. First, transcriptomic analysis on patient retinoblastoma tissues suggested that cell cycle progression was deregulated and confirmed that PLK1 pathway was upregulated. Next, antitumor activity of ON-01910.Na was investigated in both cellular and animal levels. Cytotoxicity induced by ON-01910.Na was tumor specific and… More >